Anzeige
Mehr »
Donnerstag, 03.07.2025 - Börsentäglich über 12.000 News
+210 % Kursgewinn Year to Date: Neuausrichtung nimmt Fahrt auf - jetzt exklusives CEO-Interview ansehen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Realtimekurse aktiv

WKN: A2JLMD | ISIN: US03168L1052 | Ticker-Symbol: 2DT
Tradegate
01.07.25 | 17:25
7,000 Euro
-1,41 % -0,100
1-Jahres-Chart
AMNEAL PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
AMNEAL PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
7,0507,15009:09
7,0507,15008:00

Aktuelle News zur AMNEAL PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
25.06.Amneal Pharmaceuticals LLC: Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences90Amneal holds exclusive U.S. commercialization rights; BLA filing expected in Q4 2025 Poised to be among the first wave of biosimilars in the $3.9 billion U.S. omalizumab market and an important growth...
► Artikel lesen
12.06.Amneal Pharma Gets FDA Approval For Prednisolone Acetate Ophthalmic Suspension-
12.06.Amneal Pharmaceuticals LLC: Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension140Key complex product approval in the Affordable Medicines segment this yearCommercial launch planned for third quarter of 2025 BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals...
► Artikel lesen
10.06.Amneal Pharmaceuticals bei Goldman Sachs Konferenz: Strategische Wachstumsvision5
06.06.Teva, Amneal rated Buy, Viatris Neutral as Goldman Sachs reviews generics space20
06.06.Goldman Sachs stuft Amneal Pharmaceuticals-Aktie mit neutraler Bewertung ein6
06.06.Goldman Sachs initiates Amneal Pharmaceuticals stock with neutral rating2
05.06.Amneal recalls 3 lots of a generic antibiotic after black spots found on tablets1
AMNEAL PHARMACEUTICALS Aktie jetzt für 0€ handeln
04.06.Amneal recalls oral antibiotic due to bacterial contamination1
21.05.DelveInsight Business Research, LLP: Migraine Market Enters New Era Following Satsuma Pharmaceuticals' ATZUMI and Amneal Pharmaceuticals' BREKIYA Regulatory Approval | DelveInsight341The approval of ATZUMI and BREKIYA is expected to significantly reshape the migraine market by introducing new, innovative treatment options. These therapies promise improved efficacy and...
► Artikel lesen
16.05.FDA approves Amneal's DHE migraine/cluster headache autoinjector2
15.05.Amneal gets U.S. FDA nod for Brekiya as a migraine treatment1
15.05.US FDA approves Amneal's self-administered migraine treatment1
15.05.Amneal Pharmaceuticals: FDA Approves Brekiya Injection2
15.05.Amneal erhält FDA-Zulassung für Brekiya-Autoinjektor zur Migränebehandlung6
15.05.Amneal Pharmaceuticals LLC: Amneal Receives U.S. FDA Approval for Brekiya (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults184Brekiya® becomes the first and only DHE autoinjector that allows patients to self-administer the same medication used in hospitals in a ready-to-use form Product will be available for appropriate...
► Artikel lesen
08.05.Amneal bolsters US manufacturing capacity with Apiject collaboration deal2
07.05.Amneal Pharmaceuticals, Inc. - 10-Q, Quarterly Report2
02.05.Drug Maker Amneal Highlights Strong Commercial Uptake For Parkinson's Drug But Q1 Earnings Are Mixed3
02.05.Amneal targets $3B-$3.1B in 2025 revenue with strong growth drivers1
Weiter >>
50 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen